↓ Skip to main content

HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma

Overview of attention for article published in Journal of Translational Medicine, December 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

twitter
3 X users

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
26 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma
Published in
Journal of Translational Medicine, December 2015
DOI 10.1186/s12967-015-0743-2
Pubmed ID
Authors

Feng Xue, Brandon W. Higgs, Jiaqi Huang, Chris Morehouse, Wei Zhu, Xin Yao, Philip Brohawn, Zhan Xiao, Yinong Sebastian, Zheng Liu, Yun Xia, Dong Shen, Mike Kuziora, Zhengwei Dong, Hulin Han, Yi Gu, Jianren Gu, Qiang Xia, Yihong Yao

Abstract

Orthotopic liver transplantation (OLT) can be an effective treatment option for certain patients with early stage hepatocellular carcinoma (HCC) meeting Milan, UCSF, or Hangzhou criteria. However, HCC recurrence rates post-OLT range from 20 to 40 %, with limited follow-up options. Elucidating genetic drivers common to primary and post-OLT recurrent tumors may further our understanding and help identify predictive biomarkers of recurrence-both to ultimately help manage clinical decisions for patients undergoing OLT. Whole exome and RNA sequencing in matched primary and recurrent tumors, normal adjacent tissues, and blood from four Chinese HCC patients was conducted. SiRNA knockdown and both qRT-PCR and Western assays were performed on PLCPRF5, SNU449 and HEPG2 cell lines; immunohistochemistry and RNA Sequencing were conducted on the primary tumors of Chinese HCC patients who experienced tumor recurrence post-OLT (n = 9) or did not experience tumor recurrence (n = 12). In three independent HCC studies of patients undergoing transplantation (n = 21) or surgical resection (n = 242, n = 44) of primary tumors (total n = 307), HERC5 mRNA under-expression correlated with shorter: time to tumor recurrence (p = 0.007 and 0.02) and overall survival (p = 0.0063 and 0.023), even after adjustment for relevant clinical variables. HERC5 loss drives CCL20 mRNA and protein over-expression and associates with regulatory T cell infiltration as measured by FOXP3 expression. Further, matched primary and recurrent tumors from the 4 HCC patients indicated clonal selection advantage of Wnt signaling activation and CDKN2A inactivation. HERC5 plays a crucial role in HCC immune evasion and has clinical relevance as a reproducible prognostic marker for risk of tumor recurrence and survival in patients.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 26 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 3 12%
Researcher 3 12%
Student > Master 3 12%
Other 2 8%
Student > Doctoral Student 2 8%
Other 2 8%
Unknown 11 42%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 4 15%
Agricultural and Biological Sciences 4 15%
Medicine and Dentistry 2 8%
Economics, Econometrics and Finance 1 4%
Nursing and Health Professions 1 4%
Other 2 8%
Unknown 12 46%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 June 2016.
All research outputs
#13,960,695
of 22,835,198 outputs
Outputs from Journal of Translational Medicine
#1,697
of 3,995 outputs
Outputs of similar age
#197,533
of 389,181 outputs
Outputs of similar age from Journal of Translational Medicine
#29
of 75 outputs
Altmetric has tracked 22,835,198 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,995 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 389,181 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 75 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.